Bicycle

A novel approach to targeting disease

Bicycle® molecules are a novel class of cancer therapeutics currently in development that are made from structurally constrained bicyclic peptides that can be readily conjugated to a payload. Bicycle® molecules combine the pharmacological properties normally associated with a biologic with the manufacturing and pharmacokinetic advantages of a small molecule.[1-4]

Key features of Bicycle® molecules include[4,5]:	High specificity	Targeted drug delivery	Rapid distribution into tumors	Renal elimination

What is a Bicycle® molecule?

 Monomeric Bicycle® molecules	Bicycle® molecules consist of short, fully synthetic peptides constrained with a molecular scaffold to form 2 loops that stabilize their structure and enable high-affinity and selective binding to targets[1,2,6]
 Bicycle® Drug Conjugates  Targeted/ multi-specific Bicycle® molecules  Bicycle® Radioconjugates	Bicycle® molecules can support a variety of conjugation options[2,3]: ▸ Chemical payloads ▸ Other Bicycle® peptides, for additional functionality without negatively impacting target binding ▸ Targeted radionuclides

How is a Bicycle® molecule different from an antibody-drug conjugate?

	 Bicycle® molecule	Antibody-drug conjugate
SIZE	~1-8 kDa[2-5,7]	~150 kDa[8,9]
SYNTHETIC	Yes[2,3,5,7]	No
TUMOR TARGETING	Highly specific, leading to fewer off-tumor and off-target effects[4,5,7,10]	High specificity; known off-tumor, on-target effects and off-target effects[4,11,12]
TUMOR PENETRATION	High[3-5]	Low[4,11,12]
ELIMINATION	Plasma half-life: <1 hour[13,14] to hours[7]	Half-life: 3-6 days[8,9]

In contrast to large antibody-drug conjugates, Bicycle® molecules[5,15,16]:

Are smaller and highly specific, with high tumor penetration

Rapid tissue penetration

Do not require sustained systemic exposure to deliver the drug to tumor cells

Product candidates are investigational only and are not approved medicines.

Visit **bicycletherapeutics.com** or contact **medinfo@bicycletx.com** to learn more about how Bicycle® molecules can transform treatment approaches and patients' lives.

Bicycle

A novel approach to targeting disease



Visit **bicycletherapeutics.com** or contact **medinfo@bicycletx.com** to learn more about how Bicycle® molecules have the potential to transform treatment approaches and patients' lives.

References: 1. Heinis C, et al. *Nat Chem Biol*. 2009;5(7):502-507. doi:10.1038/nchembio.184 **2.** Mudd GE, et al. *J Med Chem*. 2020;63(8):4107-4116. doi:10.1021/acs.jmedchem.9b02129 **3.** Eder M, et al. *Cancer Res*. 2019;79(4):841-852. doi:10.1158/0008-5472.CAN-18-0238 **4.** Rigby M, et al. *Mol Cancer Ther*. 2022;21(12):1747-1756. doi:10.1158/1535-7163.MCT-21-0875 **5.** Bennett G, et al. *Mol Cancer Ther*. 2020;19(7):1385-1394. doi:10.1158/1535-7163.MCT-19-1092 **6.** Baeriswyl V, et al. *ChemMedChem*. 2012;7(7):1173-1176. doi:10.1002/cmdc.201200071 **7.** Hurov K, et al. *J Immunother Cancer*. 2021;9(11):e002883. doi:10.1136/jitc-2021-002883 **8.** PADCEV (enfortumab vedotin). Prescribing information. Seagen Inc; 2025. **9.** ADCETRIS (brentuximab vedotin). Prescribing information. Seagen Inc; 2025. **10.** Bader J, et al. Presented at: 2024 American Society of Clinical Oncology (ASCO) Annual Meeting; May 31-June 4, 2024; Chicago, IL; Abstract 3088. **11.** Fu Z, et al. *Signal Transduct Target Ther*. 2022;7(1):93. doi:10.1038/s41392-022-00947-7 **12.** Mahalingaiah PK, et al. *Pharmacol Ther*. 2019;200:110-125. doi:10.1016/j.pharmthera.2019.04.008 **13.** Baldini C, et al. Presented at: 2023 American Society of Clinical Oncology (ASCO) Annual Meeting; June 2-6, 2023; Chicago, IL; Abstract 498. **14.** Duan X, et al. *Clin Cancer Res*. 2023;29(17):3395-3407. doi:10.1158/1078-0432.CCR-23-0609 **15.** Li Z, Krippendorff BF, et al. *MAbs*. 2016;8(1):113-119. doi:10.1080/19420862.2015.1111497 **16.** Thurber GM, et al. *J Theor Biol*. 2012;314:57-68. doi:10.1016/j.jtbi.2012.08.034

Bicycle